Oral combination chemotherapy in the management of AIDS-related lymphoproliferative malignancies

• Published in: Drugs (Basel) 1999, Vol.58 (Supplement 3), p.99-107
• Main Authors: REMICK, S. C, SEDRANSK, N, BALDUCCI, L, HORTON, J, RUCKDESCHEL, J. C, HAASE, R, CRAFFEY, M, SUBRAMANIAN, N, DOWLATI, A, NAZEER, T, RAMNES, C, BLANCHARD, C, MASTRIANNI, D
• Format: Article
• Language: English
• Subjects: Administration, Oral; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Chemotherapy; Hodgkin Disease - drug therapy; Humans; Lymphoma, AIDS-Related - drug therapy; Lymphoma, Non-Hodgkin - drug therapy; Medical sciences; Pharmacology. Drug treatments
• ISSN: 0012-6667; 1179-1950
• DOI: 10.2165/00003495-199958003-00014

An oral combination chemotherapy regimen initially developed for AIDS-related non-Hodgkin's lymphoma includes lomustine (CCNU), etoposide, cyclophosphamide, and procarbazine. This regimen takes advantage of oral administration, the in vitro synergy of these drugs and their first-line efficacy in lymphoma, and the ability of lomustine and procarbazine to cross the blood-brain barrier. This regimen was used to treat 38 patients with AIDS-related non-Hodgkin's lymphoma. The overall objective response rate was 66% (34% complete response rate) with a 5% CNS relapse rate, and a median survival duration of 7.0 months. One-third of the patients survived for 1 year, 11% for 2 years, and half of the patients survived free from progression of their lymphoma. On the basis of these results, this oral regimen was modified and administered to 5 patients with AIDS-related primary CNS lymphoma as part of a sequential combined-modality chemotherapy and radiation regimen. Rapid progression of CNS disease was observed in this group of patients, with a median survival duration of 1.0 month. The identical regimen was administered to 7 patients with AIDS-related Hodgkin's disease: we observed a 71% partial remission rate and a median survival duration of 7.0 months. Myelosuppression remains the most significant clinical toxicity. Our results with this oral regimen appear comparable to those of standard intravenous combination chemotherapy regimens in patients with AIDS-related non-Hodgkin's lymphoma.